What is Currently Recommended?

Two serogroup B meningococcal (MenB) vaccines are currently licensed for use among persons aged 10–25 years in the United States: MenB-FHbp (Trumenba) and MenB-4C (Bexsero). The Advisory Committee on Immunization Practices (ACIP) and CDC currently recommends routine use of MenB vaccines among persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease (Category A recommendation), including persons who have persistent complement component deficiencies; persons who have anatomic or functional asplenia; microbiologists who routinely are exposed to isolates of Neisseria meningitidis; and persons identified to be at increased risk because of a serogroup B meningococcal disease outbreak.

The ACIP and CDC recommends all adolescents and young adults aged 16–23 years may be vaccinated with MenB vaccines to provide protection against serogroup B meningococcal disease (Category B recommendation).

Source: Patton ME, Stephens D, Moore K, MacNeil JR. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep 2017;66:509–513. DOI: http://dx.doi.org/10.15585/mmwr.mm6619a6.

Additional Resources

About the Foundation
What is Meningitis B
Paper help services are available at a variety of price ranges.